Clinical trials: BCG Infection
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.
- Trial name
- NCT00427830
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Tuberculosis, Healthy
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers
Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against TB for residents in endemic areas and persons at…
- Trial name
- NCT00749034
- Testing
- VPM1002, BCG
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Malaria, Plasmodium Falciparum
Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection
The Bacillus Calmette-Guérin (BCG) vaccine, a live attenuated Mycobacterium bovis vaccine, has been used to prevent tuberculosis for almost a century, and it is still the most used vaccine in the world.
- Trial name
- BCG-EHMI (NCT02692963)
- Testing
- BCG vaccination
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Vaccine Preventable Disease, Measles
Measles and BCG Vaccines for Mother and Child
In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other…
- Conditions
- Vaccine Preventable Disease, Measles, Mother-Infant Interaction, BCG Vaccination Reaction
- Trial name
- MATVAC (NCT04899765)
- Testing
- BCG vaccine, Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Tuberculosis
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Goal of Serum Institute of India Limited (SIIL) is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis…
- Trial name
- NCT02391415
- Testing
- VPM1002, BCG, VPM1002(Hyg+)
- Where
- 4 sites in South Africa
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Tuberculosis
ID93/GLA-SE Vaccination + BCG Challenge
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2.
- Trial name
- NCT06670755
- Testing
- ID93/GLA-SE, BCG Danish
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine
BCG has marked immune stimulatory effects in both animal and human studies and observational studies suggest that BCG is associated with a non-specific reduction in mortality in areas with high infant and child mortality.
- Trial name
- NCT00126217
- Testing
- Bacille Calmette Guerin (BCG)
- Where
- Guinea-Bissau
- Volunteers
- 2,871 people
- Sponsor
- Bandim Health Project
HIV Infections
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1.
- Trial name
- HIVGP-BCG (NCT07182838)
- Testing
- HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
COVID-19, Sars-CoV2
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
A novel betacoronavirus, SARS-CoV-2, is spreading rapidly throughout the world. A large epidemic in South Africa may overwhelm available hospital capacity and healthcare resources which would be worsened by absenteeism of…
- Trial name
- NCT04379336
- Testing
- Bacille Calmette-Guérin (BCG)
- Where
- South Africa
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- TASK Applied Science
Tuberculosis
Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa
Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis (TB) for residents in endemic areas…
- Trial name
- NCT01479972
- Testing
- VPM1002, BCG
- Where
- South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Tuberculosis
BCG Revaccination Study in Diabetic and Non-Diabetic Adults
The purpose of this study is to: 1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection. 2.
- Trial name
- NCT06246851
- Testing
- BCG Danish
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19, BCG Vaccination
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is…
- Trial name
- NCT04347876
- Testing
- Tuberculin test
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Covid19
BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)
The purpose of this study is to assess the efficacy of Bacille Calmette-Guérin (BCG) vaccination compared to placebo in reducing severe Covid-19 disease among elderly residents of skilled nursing facilities.
- Trial name
- NCT04534803
- Testing
- BCG Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Harvard Medical School (HMS and HSDM)
Tuberculosis
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents
Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective…
- Trial name
- TB036 (NCT02178748)
- Testing
- MVA85A
- Where
- Uganda
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Transitional Cell Carcinoma, Bladder Cancer
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the…
- Conditions
- Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
- Trial name
- BOND (NCT01438112)
- Testing
- CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- CG Oncology, Inc.
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to…
- Trial name
- NCT05547464
- Testing
- BNT164a1, BNT164b1
- Where
- 8 sites in Mozambique, South Africa
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Tuberculosis
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
This study will assess the safety of a Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) and will evaluate if giving the vaccine by mouth, injection, or by both methods produces greater results.
- Trial name
- NCT00396370
- Testing
- BCG strain Connaught, BCG strain Danish
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
TB
Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines
This study is preliminary to proving that this vaccine could protect against tuberculosis in humans. Although there is no proven data to show that infants will benefit directly from participation in this study by being protected…
- Trial name
- NCT00480454
- Testing
- MVA 85A
- Where
- The Gambia
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine
The aim of the study is to investigate immunogenicity and safety of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years
- Trial name
- NCT06873282
- Testing
- TB/Flu-05E
- Where
- 3 sites in Russia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia